You are here: Home: BCU CME | 2005: Case 6: Select publications
 
     
 

SELECT PUBLICATIONS

Baber R et al. Therapy for menopausal symptoms during and after treatment for breast cancer: Safety considerations. Drug Saf 2005;28(12):1085-100. Abstract

Cheer SM et al. Goserelin: A review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs 2005;65(18):2639-55. Abstract

Dellapasqua S, Castiglione-Gertsch M. The choice of systemic adjuvant therapy in receptor-positive early breast cancer. Eur J Cancer 2005;41(3):357-64. Abstract

Dixon JM et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004;40(18):2742-7. Abstract

Dowsett M et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Inf luence of hormonal status and HER-2 in breast cancer — A study from the IMPACT trialists. J Clin Oncol 2005;23(11):2477-92. Abstract

Duric VM et al. Patients’ preferences for adjuvant endocrine therapy in early breast cancer: What makes it worthwhile? Br J Cancer 2005;93(12):1319-23. Abstract

Ellis MJ et al. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: Pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 2003;86(3-5):301-7. Abstract

Fatouros M et al. Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 2005;5(4):737-45. Abstract

Forbes JF et al. Choosing between endocrine therapy and chemotherapy — Or is there a role for combination therapy? Breast Cancer Res Treat 2002;75(Suppl 1):37-44. Abstract

Freedman OC et al. Using aromatase inhibitors in the neoadjuvant setting: Evolution or revolution? Cancer Treat Rev 2005;31(1):1-17. Abstract

Jonat W et al. Trends in endocrine therapy and chemotherapy for early breast cancer: A focus on the premenopausal patient. J Cancer Res Clin Oncol 2006:1-12;[Epub ahead of print]. Abstract

Kirova YM et al for the Institut Curie Breast Cancer Study Group. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41(15):2304-11. Abstract

Mitsuyama S et al. Assessment of goserelin treatment in adjuvant therapy for premenopausal patients with breast cancer in Japan-zoladex breast cancer study group trial-B. Gan To Kagaku Ryoho 2005;32(13):2071-7. Japanese. Abstract

Olivotto IA et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23(12):2716-25. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005 20;353(16):1659-72. Abstract

Seynaeve C, Brekelmans CT. Tailoring breast cancer therapy to genetic status. Lancet 2005;14-20;365(9472):1672-3. Abstract

Smith IE et al; IMPACT Trialists’ Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23(22):5108-16. Abstract

Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: Aromatase inhibitor or antioestrogen? Br J Cancer 2004;90(1):20-5. Abstract

 

  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office